[CAS NO. ] Apelin-13 TFA

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Catalog

HY-P1944A

Brand

MCE

CAS

-

DESCRIPTION

Overview

MDL	-
Molecular Weight	1664.85
Molecular Formula	C71H112F3N23O18S
SMILES	-

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ) , activating this G protein-coupled receptor with an EC ₅₀ value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome ^[1] ^[2] ^[3] .

IC50 & Target

IC ₅₀ : 0.37 nM (APJ) ^[1]

In Vivo

Apelin-13 (200 µg/kg; IP, daily for 4 weeks) improves cardiac function, improves insulin resistance, improves lipid metabolism, significantly decreases TNF-α and leptin on serum, induces the expression of Apelin-12 in serum and markedly elevates GLUT4 and p-AMPKα2 levels ^[2] .
Apelin-13 (10 and 100 μM; ICV, single dosage) increases the spontaneous discharges in the majority of pallidal neurons ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Goto-Kakizaki (GK) rats (12 weeks old; 240-280 g; fed with a high-fat diet: 66.5% standard chow, 10% lard, 20% sucrose, 2.5% cholesterol and 1% pig bile salt) ^[2]
Dosage:	200 µg/kg
Administration:	IP, daily for 4 weeks
Result:	Significantly decreased heart rate; lowered the levels of fasting plasma glucose (FPG), fasting insulin (FINS) and homeostasis model assessment for insulin resistancey (HOMA-IR); decreased serum levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein-cholesterol (LDL-C) and increased high density lipoprotein-cholesterol (HDL-C); decreased NO level, cNOS activity, TNF-α and leptin in serum; induced the expression of Apelin-12.

Animal Model:	Adult Wistar rats (SPF, 8-10 weeks, 240-280 g) ^[4]
Dosage:	10 and 100 μM
Administration:	ICV, single dosage
Result:	Increased the spontaneous discharges in the majority of pallidal neurons.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01590108	Imperial College London	Idiopathic Pulmonary Arterial Hypertension	March 2012	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 50 mg/mL ( 30.03 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.6007 mL	3.0033 mL	6.0065 mL
5 mM	0.1201 mL	0.6007 mL	1.2013 mL
10 mM	0.0601 mL	0.3003 mL	0.6007 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (60.07 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.